N-butyl-N'-isopropylurea | 25347-95-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: N-butyl-N'-isopropylurea
• 英文别名: N-n-Butyl-N'-iso-propyl-harnstoff；1-butyl-3-propan-2-ylurea
• CAS: 25347-95-9
• 化学式: C₈H₁₈N₂O
• mdl: MFCD06088058
• 分子量: 158.244
• InChiKey: YPNQRPJMMUQHGP-UHFFFAOYSA-N

物化性质

• 沸点：
  288.6±9.0 °C(Predicted)
• 密度：
  0.900±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  正溴丁烷 、 异丙基脲 在 尿素 作用下， 以58%的产率得到N-butyl-N'-isopropylurea
  参考文献：
  名称：

  Process for the N-alkylation or ureas

  摘要：

  尿素的N-烷基化过程是通过在稀释剂中，在固体碱和相转移催化剂的存在下，将尿素与烷基化剂反应实现的。

  公开号：

  US05124451A1

文献信息

• SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20190152948A1

  公开（公告）日：2019-05-23

  Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R 1 , R 2 , R 3 , R 4 , and R 5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

  具有以下化学式I的化合物，或其立体异构体或药用可接受的盐，其中R1、R2、R3、R4和R5如本文所定义，在通过作用于Tyk-2引起信号转导抑制的过程中，对IL-12、IL-23和/或IFNα的调节是有用的。
• Synthesis of urea derivatives from amines and CO2 in the absence of catalyst and solvent
  作者：Chaoyong Wu、Haiyang Cheng、Ruixia Liu、Qiang Wang、Yufen Hao、Yancun Yu、Fengyu Zhao

  DOI：10.1039/c0gc00059k

  日期：——

  Urea derivatives are obtained in mild to good yield from the reactions of primary aliphatic amines with CO2 in the absence of any catalysts, organic solvents or other additives. To optimize reaction conditions, experimental variables including temperature, pressure, the concentration of amine, reaction time etc. were studied. Satisfactory yields were obtained at the optimized conditions that are comparable

  尿素 从 脂肪族伯胺用CO 2在没有任何催化剂， 有机的 溶剂或其他添加剂。为了优化反应条件，研究了温度，压力，胺浓度，反应时间等实验变量。在优化的条件下获得了令人满意的产量，与存在下的可比性相当。催化剂 和 溶剂。对反应机理的初步研究表明，烷基氨基甲酸烷基铵迅速形成了中间体，然后通过分子内脱水形成了最终产物。
• Cannabinoid receptor modulators
  申请人：Chackalamannil Samuel

  公开号：US20070197628A1

  公开（公告）日：2007-08-23

  A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, is useful in treating diseases, disorders, or conditions such as obesity, metabolic disorders, addiction, diseases of the central nervous system, cardiovascular disorders, respiratory disorders, and gastrointestinal disorders.

  具有通式（I）的一种化合物：或其药用盐、溶剂合物或酯，可用于治疗肥胖、代谢紊乱、成瘾、中枢神经系统疾病、心血管疾病、呼吸系统疾病和消化系统疾病等疾病、紊乱或症状。
• NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Gopalan Balasubramanian

  公开号：US20090182143A1

  公开（公告）日：2009-07-16

  The present invention relates to novel heterocyclic compounds, their analogs, their tautomers, their regioisomers, their stereoisomers, their enantiomers, their diastereomers, their polymorphs, their pharmaceutically acceptable salts, their appropriate N-oxides, their pharmaceutically acceptable solvates and their pharmaceutical compositions containing them. The present invention more particularly relates to novel Phosphodiesterase type 4 (PDE4) inhibitors of the Formula (1), their analogs, tautomers, enantiomers, diasteromers, regioisomers, stereoisomers, polymorphs, pharmaceutically acceptable salts, appropriate N-oxide, pharmaceutically acceptable solvates and the pharmaceutical compositions containing them.

  本发明涉及新型杂环化合物、它们的类似物、互变异构体、位置异构体、立体异构体、对映异构体、顺反异构体、多晶型、药学上可接受的盐、适当的N-氧化物、药学上可接受的溶剂和含有它们的制药组合物。本发明更特别地涉及式（1）的新型磷酸二酯酶4（PDE4）抑制剂、它们的类似物、互变异构体、对映异构体、顺反异构体、位置异构体、立体异构体、多晶型、药学上可接受的盐、适当的N-氧化物、药学上可接受的溶剂和含有它们的制药组合物。
• Process for the N-alkylation of ureas
  申请人：Chemie Linz Gesellschaft m.b.H.

  公开号：US05169954A1

  公开（公告）日：1992-12-08

  Process for the N-alkylation of ureas by reacting a urea with an alkylating agent in the presence of a solid base and a phase transfer catalyst in a diluent.

  在稀释剂中，通过在固体碱和相转移催化剂的存在下，将脲与烷基化剂反应，进行脲的N-烷基化过程。